Department of Physiological Sciences, Center of Biological and Health Science, Federal University of São Carlos, Rod. Washington Luis, Km 235-SP-310, São Carlos CEP 13.565-905, São Paulo, Brazil.
Department of Gerontology, Center of Biological and Health Science, Federal University of São Carlos, Rod. Washington Luis, Km 235-SP-310, São Carlos CEP 13.565-905, São Paulo, Brazil.
Biochim Biophys Acta Mol Cell Res. 2019 Dec;1866(12):118536. doi: 10.1016/j.bbamcr.2019.118536. Epub 2019 Aug 26.
Integrins are cell receptors that mediate adhesion to the extracellular matrix (ECM) and regulate cell migration, a crucial process in tumor invasion. The αβ integrin recognizes the arginine-glycine-aspartic acid (RGD) motif in ECM proteins and it can be antagonized by RGD-peptides, resulting in decreased cell migration and invasion. RGD-based drugs have shown disappointing results in clinical trials; however, the reasons for their lack of activity are still obscure. Aiming to contribute to a better understanding of the molecular consequences of integrin inhibition, we tested a recombinant RGD-disintegrin (DisBa-01) in two types of murine cell lines, breast tumor 4T1BM2 cells and L929 fibroblasts. Only tumor cells showed decreased motility and adhesion, as well as morphologic alterations upon DisBa-01 treatment (100 and 1000 nM). This result was attributed to the higher levels of αβ integrin in 4T1BM2 cells compared to L929 fibroblasts making the former more sensitive to DisBa-01 blocking. DisBa-01 induced cell cycle arrest at the S phase in 4T1BM2 cells, but it did not induce apoptosis, which was consistent with the decrease in caspase-3, 8 and 9 expression at mRNA and protein levels. DisBa-01 increases PI3K, Beclin-1 and LC3B expression in tumor cells, indicators of autophagic induction. In conclusion, αβ integrin blocking by DisBa-01 results in inhibition of adhesion and migration and in the activation of an autophagy program, allowing prolonged survival and avoiding immediate apoptotic death. These observations suggest new insights into the effects of RGD-based inhibitors considering their importance in drug development for human health.
整合素是细胞受体,介导细胞与细胞外基质(ECM)的黏附,并调节细胞迁移,这是肿瘤侵袭的关键过程。αβ整合素识别细胞外基质蛋白中的精氨酸-甘氨酸-天冬氨酸(RGD)基序,可被 RGD 肽拮抗,从而导致细胞迁移和侵袭减少。基于 RGD 的药物在临床试验中效果不佳;然而,其缺乏活性的原因仍不清楚。为了更好地了解整合素抑制的分子后果,我们在两种类型的鼠细胞系,乳腺癌 4T1BM2 细胞和 L929 成纤维细胞中测试了一种重组 RGD 解整合素(DisBa-01)。只有肿瘤细胞在 DisBa-01 处理后表现出运动和黏附能力降低,以及形态改变(100 和 1000 nM)。这一结果归因于 4T1BM2 细胞中 αβ 整合素水平高于 L929 成纤维细胞,使前者对 DisBa-01 阻断更敏感。DisBa-01 在 4T1BM2 细胞中诱导 S 期细胞周期停滞,但不诱导细胞凋亡,这与 caspase-3、8 和 9 在 mRNA 和蛋白水平表达下降一致。DisBa-01 增加肿瘤细胞中 PI3K、Beclin-1 和 LC3B 的表达,这是自噬诱导的标志物。总之,DisBa-01 阻断 αβ 整合素导致黏附和迁移的抑制,并激活自噬程序,从而延长了细胞的存活时间,避免了细胞立即凋亡。这些观察结果为基于 RGD 的抑制剂的作用提供了新的见解,考虑到它们在人类健康药物开发中的重要性。